US on track to get 2nd vaccine as FDA panel reviews Moderna data
The United States is on the cusp of a second vaccine for COVID-19, with a key Food and Drug Administration panel set to review data Thursday from Moderna that suggests its two-dose vaccine is safe and 94% effective.
An endorsement from the independent federal advisers would pave the way for an official green light by the FDA to begin distributing next week some 5.9 million Moderna doses to the nation’s front-line health care workers and nursing home residents. An internal assessment by the FDA already found that the Moderna data show the benefits likely outweigh the risks.
The Moderna batch would be in addition to the 6.4 million doses of the Pfizer/BioNTech vaccine that started to roll out this week after being the first to get emergency-use authorization.

One primary difference is that the Modern vaccine requires fewer specific handling instructions because it does not need ultra-cold storage conditions like the Pfizer/BioNTech one.
Moderna also is seeking authorization to use its vaccine on people ages 18 and older, whereas Pfizer’s enrollment of older teens in clinical trials this fall paved the way for authorization of anyone 16 and older.
ABC News' Anne Flaherty contributed to this report.






